Berlin, Germany
TME Pharma is a clinical-stage biotechnology company headquartered in Germany, specializing in developing novel therapies targeting the tumor microenvironment (TME) which is crucial in treating aggressive forms of cancer. With a mission to enhance treatment outcomes, the company’s platform aims at breaking down tumor barriers and blocking repair mechanisms.
The key asset, NOX-A12, operates through dual mechanisms offering broad oncology indications, specifically showing promise in treating brain cancer such as glioblastoma (GBM). Notably, TME Pharma is in a strategic collaboration with Merck & Co. / MSD to assess the potential of NOX-A12 in combination with KEYTRUDA® for pancreatic and colorectal cancers.
Founded in 1998, the company has a proprietary pipeline including NOX-E36 targeting cancer spread and immune privileges. The last reported investment was a €2.35M post-IPO equity secured on June 17, 2024. As TME Pharma navigates the complex oncology landscape, its focus on TME and collaborations are pivotal for long-term growth and innovation in cancer therapies.
Sensei Bio
